<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01356914</url>
  </required_header>
  <id_info>
    <org_study_id>CV203-010</org_study_id>
    <secondary_id>2010-022947-39</secondary_id>
    <nct_id>NCT01356914</nct_id>
  </id_info>
  <brief_title>Pacemaker Holter Assessment of the Effect of BMS-914392 on Atrial Fibrillation Burden</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, 4-Way Crossover Study to Evaluate the Safety, Tolerability and Effect on Atrial Fibrillation Burden of BMS-914392 in Patients With Paroxysmal Atrial Fibrillation and Permanent Pacemaker</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether treatment with BMS-914392 is safe, well
      tolerated and associated with a reduction of atrial fibrillation burden in patients with
      paroxysmal atrial fibrillation and permanent pacemaker.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial Fibrillation Burden</measure>
    <time_frame>At screening (baseline)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Atrial Fibrillation Burden</measure>
    <time_frame>Prior to randomization to study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Atrial Fibrillation Burden</measure>
    <time_frame>On Day 1 of each cross-over period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Atrial Fibrillation Burden</measure>
    <time_frame>On Day 8 of each cross-over period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Atrial Fibrillation Burden</measure>
    <time_frame>On Day 22 of each cross-over period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events and type of adverse events</measure>
    <time_frame>At Day 1 of each cross-over period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events and type of adverse events</measure>
    <time_frame>At Day 8 of each cross-over period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events and type of adverse events</measure>
    <time_frame>At Day 22 of each cross-over period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Atrial fibrillation (AF) episodes</measure>
    <time_frame>At Day 1 of each cross-over period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of AF episodes</measure>
    <time_frame>At Day 8 of each cross-over period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of AF episodes</measure>
    <time_frame>At Day 22 of each cross-over period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of AF episodes</measure>
    <time_frame>At Day 1 of each cross-over period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of AF episodes</measure>
    <time_frame>At Day 8 of each cross-over period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of AF episodes</measure>
    <time_frame>At Day 22 of each cross-over period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>At Day 1 of each cross-over period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>At Day 8 of each cross-over period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>At Day 22 of each cross-over period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of AF (SAF) scale score at the end of each study period</measure>
    <time_frame>At Day 1 of each cross-over period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of AF (SAF) scale score at the end of each study period</measure>
    <time_frame>At Day 8 of each cross-over period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of AF (SAF) scale score at the end of each study period</measure>
    <time_frame>At Day 22 of each cross-over period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram (ECG) intervals (PR, QRS, RR, QT, QTc)</measure>
    <time_frame>At Day 1 of each cross-over period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram (ECG) intervals (PR, QRS, RR, QT, QTc)</measure>
    <time_frame>At Day 8 of each cross-over period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram (ECG) intervals (PR, QRS, RR, QT, QTc)</measure>
    <time_frame>At Day 22 of each cross-over period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMS-914392 plasma concentrations and exposures during each study period</measure>
    <time_frame>At Days 1, 8 and 22 of each cross-over period</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Treatment A: BMS-914392</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: BMS-914392</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C: BMS-914392</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-914392</intervention_name>
    <description>Tablets, Oral, 10 mg, Every Day (QD), 20 days</description>
    <arm_group_label>Treatment A: BMS-914392</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-914392</intervention_name>
    <description>Tablets, Oral, 10 mg, Three Times Daily (TID), 20 days</description>
    <arm_group_label>Treatment B: BMS-914392</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-914392</intervention_name>
    <description>Tablets, Oral, 20 mg, Three Times Daily (TID), 20 days</description>
    <arm_group_label>Treatment C: BMS-914392</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets, Oral, 0 mg, Three Times Daily (TID), 20 days</description>
    <arm_group_label>Treatment D: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Paroxysmal atrial fibrillation (AF)

          -  Programmable dual chamber pacemaker with appropriate arrhythmia diagnostics.

          -  1-50% AF burden on pacemaker interrogation at screening.

          -  Women of childbearing potential (WOCBP) and men must be using an acceptable method of
             contraception to avoid pregnancy.

        Exclusion Criteria:

          -  Persistent or permanent AF.

          -  AF Burden &lt;1% or &gt; 50%.

          -  Current or history of neurological diseases and mental disorders.

          -  Ejection Fraction &lt; 45%.

          -  Severe mitral or aortic valve dysfunction.

          -  TIA (Transient Ischemic Attack) within last 12 months.

          -  Acute coronary syndrome in the last 2 months.

          -  Previous AF ablation.

          -  Cardioversion in last 3 months.

          -  Current kidney or liver disease, or current cancer.

          -  History of neurological and mental disorders.

          -  Major surgery within 4 weeks of first dose (cardiac surgery within 4 months).

          -  Screening lab test results outside of allowed limits per protocol.

          -  QTcF &gt; 450 msec.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eastbourne General Hospital</name>
      <address>
        <city>Eastbourne</city>
        <zip>BN21 2UD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2011</study_first_submitted>
  <study_first_submitted_qc>May 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2011</study_first_posted>
  <disposition_first_submitted>September 23, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>September 23, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 12, 2015</disposition_first_posted>
  <last_update_submitted>September 23, 2015</last_update_submitted>
  <last_update_submitted_qc>September 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

